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Background: Post-stroke pain is one of the most common sequelae of stroke, which
stands among the leading causes of death and adult-acquired disability worldwide. The
role and clinical efficacy of opioids in post-stroke pain syndromes is still debated.
Objectives: Due to the important gap in knowledge on the management of post-stroke
pain, this systematic review aimed at assessing the efficacy of opioids in post-stroke pain
syndromes.
Methods: A literature search was conducted on databases relevant for medical scientific
literature, i.e. PubMed/MEDLINE, Scopus, Web of Science and Cochrane Library
databases from databases inception until August 31st, 2020 for clinical trials assessing
the effects of opioids and opioid antagonists on pain reduction and pain related symptoms
in patients with post-stroke pain syndromes. Studies assessing the effects of other
medications (e.g., tricyclic antidepressant, pregabalin) or non - pharmacological
management strategies (e.g., neurostimulation techniques) were excluded. The
selected studies have been subjected to examination of the risk of bias.
Results: The literature search retrieved 83,435 results. After duplicates removal, 34,285
articles were title and abstract screened. 25 full texts were assessed and 8 articles were
identified to be eligible for inclusion in the qualitative summary and narrative analysis, of
which three were placebo-controlled and two were dose-response. Among placebo-
controlled studies, two evaluated the analgesic effect of morphine and one assessed the
effects of the opioid antagonist naloxone on patients with central post-stroke pain. With
regard to dose-response studies, both were on patients with central post-stroke pain, one
assessing the efficacy of levorphanol, and the other on naloxone. Seven out of eight
included studies showed an overall slight analgesic effect of opioids, with less consistent
effects on other pain-related symptoms (e.g., mood, quality of life). The randomized
controlled trials were subjected tometa-analysis and rating of the quality of evidence for the
two outcomes considered according to GRADE (Grading of Recommendations,
Assessment, Development and Evaluations) system. The overall results are
inconclusive because of the small number of studies and of patients.
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Conclusions: The limited number of the included studies and their heterogeneity in terms
of study design do not support the efficacy of opioids in post-stroke pain and in pain-
related outcomes. Large double-blind randomized clinical trials with objective assessment
of pain and related symptoms are needed to further investigate this topic.
Keywords: post-stroke pain, stroke, pain, central pain, opioids, rehabilitation, systematic review, meta-analysis
INTRODUCTION
Post-stroke Pain
Stroke stands among the leading causes of death and adult-
acquired disability with 13.7 million new strokes every year
worldwide (Collaborators, 2019). Post-stroke pain is one of the
most poorly understood complications, arising either in the acute,
but mainly in the subacute or chronic stages (i.e., often within 6
months) of stroke (Merskey, 1994) . The prevalence of post-
stroke pain varies largely depending on the definition of pain;
the musculoskeletal pain appears to be the most common being
reported in up to 72% of stroke patients (Harrison and Field,
2015). While post-stroke pain syndromes in general are
estimated to affect up to 30–40% of stroke survivors
(Paolucci et al., 2016), central post-stroke pain (CPSP) is
more rare: definite CPSP was found in 3.5%, definite/
probable in 5.8% and CPSP-like pain or dysesthesia in 6.7%
of patients in a specific population-based study of post-stroke
pain (Klit et al., 2011). Pain after stroke can remarkably reduce
the quality of life, causing depression, anxiety and sleep
disorders making rehabilitation more difficult.
Post-stroke Pain Syndromes
Pain after stroke is often under-reported, being diagnosed only if
actively searched by the clinician (Harrison and Field, 2015).
There are multiple types of post-stroke pain syndromes that can
also occur in combination, with both neuropathic and nociceptive
features. The most common types of pain after stroke include
CPSP, pain secondary to spasticity, shoulder pain, complex
regional pain syndrome (i.e., CRPS), and headache (O’Donnell
et al., 2013). Dysesthesia and allodynia often occur and the
symptoms generally develop within the area corresponding to
the lesion with frequent involvement of face, hand and foot, but
sometimes also of thigh and shoulder (Kim, 2014). In particular,
CPSP is often characterized by dysesthesia, constant or
intermittent pain and hyperalgesia/allodynia (Harrison and
Field, 2015). CPRS is of type I when nerve lesion is not
identifiable, while of type II when there is a definite nerve lesion.
Treatment and Limitations
Treatment of post-stroke pain is made challenging by the lack of
universally accepted guidelines (Kim, 2014), due to the paucity of
high quality evidence from controlled clinical trials guiding
pharmacological management and, expecially, for non
neuropathic syndromes despite their high frequency (Hansson,
2004). In neuropathic pain, tricyclic antidepressants (e.g.,
amytriptiline), serotonin and norepinephrine reuptake
inhibitors (e.g., duloxetine) and calcium channel α2δ ligands
(e.g., gabapentin or pregabalin) are recommended as first-line
agents, but data supporting their use is based on studies in
peripheral neuropathic pain, while the evidence in central
neuropathic pain is very limited (Mulla et al., 2015). A single
study suggested lamotrigine to have a moderate effect on CPSP
(Klit et al., 2009). Botulinum toxin injections represent the gold
standard for the treatment of post-stroke spasticity and related
pain (Hillis, 2020). Given their potential for misuse and other
adverse effects (McNicol et al., 2013), opioids stand among the
third-line therapy and evidence on their effectiveness for post-
stroke pain syndromes is even more limited.
Aim of the Research
The aim of manuscript is to conduct a systematic review and
meta-analysis of evidence on the efficacy of opioid and opioid
antagonist medications, important and useful under the
recommended conditions (Morrone et al., 2017), for reducing
post strokepain and improving pain-related symptoms. Agonists
and antagonists at opioid receptors were included in the search.
In the brain area subjected to stroke, altered perfusion
(Strahlendorf et al., 1980) and changes in opioid
neurotransmission (Baskin and Hosobuchi, 1981; Willoch
et al., 2004) were suggested to be positively affected by
naloxone; incidentally, opioids can reduce blood flow during
cerebral ischemia, through inhibition of the release of
noradrenaline in the locus coeruleus (Budd, 1985). Moreover,
naloxone and kappa opioid receptor antagonists were tested in
acute ischemic stroke showing in some cases benefit and
improvement of neurological conditions (Fallis et al., 1984;
Jabaily and Davis, 1984; Perey et al., 1984; Adams et al., 1986;
Czlonkowska and Cyrta, 1988; Federico et al., 1991; Czlonkowska
et al., 1992; Clark et al., 1996; Lyden, 1996; Clark et al., 2000).
Levorphanol, an opioid agonist with high affinity for all the mu,
delta and kappa opioid receptors, reported to interact with both
N-methyl-D-aspartate (NMDA) receptors and serotonin and
norepinephrine uptake (Codd et al., 1995), was included
because of its favourable pharmacodynamic and
pharmacokinetic characteristics and it showed efficacy in
neuropathic pain (Le Rouzic et al., 2019). Oliceridine, a novel
mu opioid agonist, was included because it can confer analgesia
with less respiratory depression (Dahan et al., 2020).
METHODS
This work was conducted according to the PRISMA (Preferred
Reporting Items for Systematic reviews and Meta-Analyses)
recommendations (Liberati et al., 2009; Moher et al., 2009).
The systematic review focused on the following question: are
opioids effective in reducing pain after stroke and improving
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pain-related symptoms? Detailed PICOS (i.e., participants,
interventions, comparisons, outcomes, study design)
framework is shown below:
Participants: patients with pain after stroke; - Intervention:
opioid and opioid antagonist medications; - Comparison:
placebo or usual/other treatment; - Outcomes: 1)
improvement of assessed pain intensity and 2) of pain-
related outcomes (e.g., mood, quality of life); - Design of
the studies: clinical trials.
The efficacy and safety of opioids on intractable post-stroke
pain is a fundamental gap of knowledge due to the lack of studies.
Therefore, our systematic review andmeta-analysis addresses this
broad question, providing an overview of the existing evidence
also originating from studies with different design and prompting
further future research (Peters et al., 2015). This research aims at
highlighting whether opioids and their antagonists are used in
post-stroke pain, including medications with different
mechanisms of action, and if they are safe and efficacious on
the primary outcome of pain reduction and on secondary related
outcomes like physical functioning.
Eligibility Criteria
Studies eligible to be included in this systematic review and meta-
analysis were required to meet the following criteria:
clinical trials assessing the effects of opioids on pain in post-
stroke patients. No restrictions were placed on the publication
date, study duration or follow-up; - patients of any age or
ethnicity with post-stroke pain; - interventions include opioids.
Studies meeting the following criteria were excluded from the
review:
in vitro and in vivo animal studies, narrative or systematic
reviews and meta-analysis, abstracts and congress
communications, proceedings, editorials and book chapters;
- clinical trials assessing the effects of other pharmacological
treatments (e.g., tricyclic antidepressant, pregabalin) or non -
pharmacological management strategies (e.g.,
neurostimulation techniques); - studies not published in
English.
Primary outcomes of interest were changes in objective
measures of pain intensity (e.g., pain visual analog scale VAS)
and secondary outcomes of interest were changes in pain-related
outcomes (e.g., quality of life and physical functioning).
Search Strategy
The literature search was conducted on PubMed/MEDLINE,
Scopus, Web of Science and Cochrane Library databases for
peer-reviewed studies on opioid medications for the treatment
of post-stroke syndromes and published from databases
inception until August 31st, 2020 (date of last search). The
search strings consisted in a combination of the following
keywords: “stroke,” “post-stroke pain,” “pain after stroke,”
“central post-stroke pain,” “CPSP,” “shoulder post-stroke,”
“thalamic pain syndrome,” “central pain syndrome,” “shoulder
hand syndrome,” “complex regional pain”; “Dejerine Roussy,”
“facial pain,” “headache,” “facial neuralgia,” “trigeminal
autonomic cephalalgia,” “temporomandibular joint disorders,”
“allodynia,” “pain secondary to spasticity,”musculoskeletal pain,”
“myofascial pain,” “neuropathic pain,” “opioids,” “methadone,”
“tramadol,” “codeine,” “morphine,” “buprenorphine,”
“oxycodone,” “fentanyl,” “tapentadol,” “loperamide,”
“oxymorphone,” “hydrocodone,” “levorphanol,” “sufentanil,”
“remifentanil,” “R-dihydroetorphine,” “Morphine-6-
glucuronide,” “oliceridine,” “naloxone,” “naltrexone.”
Study Selection
Two authors independently screened titles and abstracts of the
studies in agreement to the previously established inclusion and
exclusion criteria. The reference lists of relevant papers were
inspected for additional studies potentially missed in the database
search. Any disagreement was planned to be solved by consensus
or by consulting a third Author.
Data Collection Procedure
Two authors independently extracted the following data,
according to the PICOS framework discussed above: study
design, sample size, subtype of post-stroke pain syndrome,
interventions, route of drugs administration, comparators,
outcomes of interest (primary and secondary), drop-out rates,
adverse effects.
Data Analysis
A systematic and descriptive analysis of the results was provided
with information presented in the text and tables. The narrative
synthesis has been carried out according to the Cochrane
Consumers and Communication Review Group guidelines
(Ryan, 2013). Risk of bias and quality of the studies have been
assessed, considering study limitations including lack of
allocation concealment, lack of blinding, selective outcome
reporting bias, inadequate sample or lack of sample size
calculation. The revised Cochrane risk of bias tool for
randomized trials RoB2 (Sterne et al., 2019) has been used.
only the randomized clinical trials included were subjected to
meta-analysis to assess imprecision. Indeed, the quality of the
body of evidence for both outcomes was rated through the
GRADE (Grading of Recommendations, Assessment,
Development and Evaluations) system providing the evidence
profile including the quality assessment and the summary of
findings (Guyatt et al., 2011). Absolute and relative risk with 95%
confidence intervals (CI) were calculated using the Cochrane
Review Manager 5.3 (RevMan5.3; Copenhagen: The Nordic
Cochrane Center, The Cochrane Collaboration). The random
effect model (DerSimonian and Kacker, 2007) was used to
manage eventual heterogeneity of the studies and to assess
intra- and inter-study variation. In particular, for the
assessment of inconsistency in results, since the retrieved
studies number is small, the Higgins I2 value was calculated to
assess the heterogeneity of the studies (Higgins and Thompson,
2002). Relative risk below one favors the intervention (opioids)
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rather than the control/other treatment. Subgroup analysis,
sensitivity testing and meta-regression have been performed to
evaluate the impact and the causes of heterogeneity and
publication bias has been assessed through Egger’s linear
regression test to measure funnel plot asymmetry, adjusted
through “trim and fill” method (Egger et al., 1997; Duval and
Tweedie, 2000; Sterne and Egger, 2001).
RESULTS
Identification and Selection of the Studies
The literature search retrieved a total of 83,435 results. The 83,435
references obtained have been searched for duplicates, leaving
34,285 articles to screen. After titles and abstract screening, not
original articles like reviews, book chapters and conference
proceedings have been eliminated leaving 24,950 titles and
abstracts to screen. After elimination of in vivo and in vitro
studies 2,736 have been screened to exclude observational and
retrospective studies, thus leading to 2,531 clinical studies, among
which 25 were obtained for full-text reading. One of these trials
(Fallis et al., 1984) was not available in full text and one significant
paper (Yamamoto et al., 1991) was further identified by the
inspection of the reference lists of the relevant records. Eight
studies met the inclusion criteria and were therefore included in
qualitative synthesis. The four randomized controlled trials
(RCTs) (Bainton et al., 1992; Attal et al., 2002; Maier et al.,
2002; Rowbotham et al., 2003) were subjected to meta-analysis.
The selection process is illustrated in the PRISMA flow diagram
(Figure 1).
Qualitative Summary and Narrative Analysis
The 8 included articles (Budd, 1985; Yamamoto et al., 1991;
Bainton et al., 1992; Yamamoto et al., 1997; Attal et al., 2002;
Maier et al., 2002; Rowbotham et al., 2003; Saitoh et al., 2003)
were clinical trials meeting the previously mentioned inclusion
criteria. Studies were grouped according to the intervention
(i.e., type of opioid medication), following the Cochrane
Consumers and Communication Review Group guidelines
(Ryan, 2013). Details of the included studies are summarized
in Tables 1 and 2.
Morphine
Two studies assessed the analgesic effect of morphine on CPSP
(Attal et al., 2002; Maier et al., 2002). Attal et al. (2002) performed
a double-blind, placebo-controlled, crossover study with the two-
fold aim to evaluate the efficacy of intravenous morphine on
spontaneous and evoked pain and the long-term benefit of oral
morphine on neuropathic pain caused by spinal cord injury or
stroke. They reported that the analgesic effect of intravenous
morphine regarded only some components of evoked pain
(i.e., the intensity of brush-induced allodynia) and that the
effects of morphine on ongoing pain were not significantly
different from those of the placebo and some patients were
reported to receive other pharmacological treatment for pain.
Regarding the long-term benefit of oral morphine, only three
patients were reported to be still treated after 1 year with
persistent pain relief, while the others dropped out before
three months due to side effects. It is however unclear
whether the patients still on oral morphine treatment at 1 year
were those belonging to the group of neuropathic pain caused by
stroke or by spinal cord injury. Maier et al. (2002) conducted a
prospective, randomized, double-blind, placebo-controlled,
crossover study on forty-nine patients with either neuropathic
(of which only two had CPSP) or nociceptive pain syndromes,
assessing the efficacy and effectiveness of 1 week of oral morphine
administration. In fact, the MONTAS study assessed the efficacy
of morphine on chronic non-tumor associated pain syndromes
(Maier et al., 2002). An interdisciplinary consensus protocol on
compulsory and optional treatments for pain, excluding strong
opioids was followed before inclusion. The two patients with
CPSP were classified as partial responders according to the
reduction from 7.8 to 5.6 of mean pain intensity measured
with an 11 points Numerical Rating Scale (NRS) and to the
overall tolerability of adverse effects connected with opioid
medications. Pain reduction was reported to correlate with
improvement of physical function. Moreover, the Authors
found a reduction of pain disability, depression score, mood
and exercise endurance, secondary pain-related outcomes. The
pharmacological background of intractable CPSP was
characterized in three studies through morphine tests: two by
Yamamoto and coworkers (Yamamoto et al., 1991; Yamamoto
et al., 1997) and one by Saitoh and collaborators (Saitoh et al.,
2003). The first study evaluated deafferentation pain using the
morphine/thiamylal test enrolling twenty-five patients suffering
from intractable deafferentation pain (thalamic/suprathalamic
lesions n  16; brainstem lesions n  2; spinal cord lesions n
 2; peripheral nerve lesions n  5) (Yamamoto et al., 1991). The
morphine test consists in intravenously administering 3 mg
morphine hydrochloride every 5 min up to reach 18 mg,
followed by injection of naloxone to reverse thus confirming
the effect of morphine, and assessing pain through a visual analog
scale at 5 min intervals (Yamamoto et al., 1991). All the patients
included were resistant to pharmacological therapy. According to
the results, only two patients with thalamic or suprathalamic
lesions were responding to morphine and thiamylal (Yamamoto
et al., 1991). In the second study by Yamamoto et al. (1997) thirty-
nine patients with intractable hemibody CPSP associated with
dysesthesias and allodynia (twenty-five affected by a small
thalamic infarct or hemorrhage and fourteen affected by
infarct or hemorrhage in the posterior limb of the internal
capsule or subcortical parietal area sparing the thalamus) were
subjected to the morphine and thiamylal tests and only twenty-
three recent cases were subjected to the ketamine test. All the
patients had been received treatment with tricyclic and
heterocyclic antidepressants, benzodiazepines and non-narcotic
analgesics without satisfactory pain reduction. During this study,
eight patients with CPSP were sensitive to morphine experiencing
transient satisfactory pain reduction (Yamamoto et al., 1997). In
the study by Saitoh and colleagues (Saitoh et al., 2003) nineteen
patients with central and peripheral deafferentation pain (seven
who had thalamic hemorrhage, one putaminal hemorrhage, one
pontine hemorrhage, six brachial plexus injury, two phantom
limb pain, one spinal cord injury and one pontine injury) of
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which eighteen underwent drug challenge test and pain was
assessed through a visual analog scale and the McGill Pain
Questionnaire. All the patients were treated with various
medications including NSAIDs, anticonvulsants and
antidepressants also used in combination, without sufficient
reduction of pain. Among these patients, five were sensitive to
morphine (Saitoh et al., 2003).
Levorphanol
One study (Rowbotham et al., 2003) evaluated the efficacy of low
and high doses of the opioid agonist levorphanol on eighty-one
patients with neuropathic pain of different aetiology (patients with
CPSP were ten). All patients had not achieved pain relief with
previous non opioid medications and a trend towards previous use
of low dose opioid was reported in the low-strength group.
Compared to low ones, high doses of levorphanol resulted in
higher rates of reduction in the intensity of neuropathic pain,
considering the whole patient sample; however, high doses of
levorphanol also resulted in more severe side effects that led to
higher drop-out rates. Despite the additional outcomes of affective
distress and interference with functioning were reduced, no
difference between groups were observed. Moreover, pain relief
was less frequent for patients suffering from CPSP. Pain effect on
physical functioning was evaluated only in this study (Rowbotham
et al., 2003).
Naloxone
Two studies assessed the effect of the opioid antagonist naloxone
on CPSP (Budd, 1985; Bainton et al., 1992). Budd (1985)
performed a single group study on thirteen patients with
pain due to thalamic syndrome resistant to prior analgesic or
other therapies and reported analgesia, assessed by direct
questioning, for seven patients after twenty intravenous
administrations of naloxone. The duration of the effects
FIGURE 1 | Process of selection of the studies eligible for the qualitative analysis according to the PRISMA guidelines (Moher et al., 2009).
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six brachial plexus injury,
two phantom limb pain,
one spinal cord injury and
one pontine injury)
Intervention First phase: intravenous
infusion of morphine
(9–30 mg; mean
dosage, 16 mg) for a 20
-minute period; infusion
of saline solution was
conducted on a
separate session after
2 weeks Second phase:
within one week after
the second infusion, all
patients began to take
sustained release oral
morphine (starting from
20 mg/d during four




of naloxone (8 mg in a
20 ml manufacturer’s
vehicle) or of placebo
(20 ml of saline
solution).The second
injection took place 2 or







naloxone (from 4.0 to
8.0 mg)
Sustained-release
morphine in the first
week and placebo in



























Intravenous Intravenous Oral Oral Intravenous Intravenous Intravenous
Comparator Saline (0.9% NaCl) Saline (0.9% NaCl) NA NS Low-strength
levorphanol
Saline (0.9% NaCl) Saline (0.9% NaCl) Saline (0.9% NaCl)
CPSP, Central Post-Stroke Pain; DS, Depression Scale; MPI, Multidimensional Pain Inventory; NA, not applicable; NaCl, sodium chloride; NRS, Numerical Rating Scale; NS, not specified; OAES, Opiate Agonist Effects Scale; OWS, Opiate



























































First phase: spontaneous pain 
ongoing pain intensity (VAS);
evoked pain  intensity of allodynia
(VAS); intensity of mechanical pain
(VAS); intensity of thermal pain
(VAS) Second phase: mean pain
intensity (VAS)
Pain intensity (VAS and 5 – word
pain score) assessed
immediately after the injection
Changes in pain state (direct
questioning)
Pain intensity (NRS) Pain
tolerability (VRS) Rate and intensity
of adverse effects (VRS)
Daily pain intensity (VAS) Pain
relief (NRS)
Pain assessed through a visual
analog scale
Pain assessed through a visual
analog scale
Pain assessed through a visual




Global assessment of pain relief
(complete, a lot, moderate, slight,
none, or worse pain) Reports of
side effects (direct questioning)
Long-term pain intensity
reduction (VAS)
Pain relief duration Sleep quality (VRS) Physical
fitness and endurance (NRS) Pain
disability index (NRS) Mental state
and mood (NRS) Depression (DS)
Intensity of symptoms (SC-S)
Mood disturbances (PMS) Quality
of life (MPI) Cognitive functioning
(SDMT) Symptoms related to
agonist and antagonist activity




Results aFirst phase: morphine
significantly reduced dynamic
mechanical allodynia (in 9 patients
reduction of 50% of pain intensity -
VAS) respect to placebo; no
significant differences on ongoing
pain intensity between morphine
and placebo aSecond phase: 3
patients out of 15 still took oral
morphine after one year follow-up,
reporting a 50–70% reduction of
mean pain intensity measured with
VAS
Inconsistent effects of naloxone
compared to placebo on pain
intensity reduction: mean ±SE of
VAS for naloxone (− 9.35 ± 4.86)
vs saline (− 10.05 ± 4.99) Pain
relief obtained either with
naloxone or placebo was not
maintained beyond one day after
the injection
7 patients experienced analgesia
within 5 min of the completion of
naloxone administration lasting
from 4 days to 2 and a half years
2 CPSP patients were classified as
partial responders (amean pain
intensity from 7.8 to 5.6 after
morphine; tolerable side effects)
aPain intensity reduction
correlated with improvement of
physical function aOther
secondary outcomes measures
did not show significant
improvement after morphine
treatment compared to placebo
aPain reduction from baseline
(high-strength 23 mm vs low-
strength 14 mm VAS) a66%
patients under high-strength
treatment reported pain relief
aNo significant changes in total
mood disturbance in either
treatment group aNo significant
changes in quality of life measures
in either treatment group aNo
significant changes in cognitive
functioning in either treatment
group aFewer capsules each day
for the high-strength group
compared to low-strength (11.9 ±
5.5 vs. 18.3 ± 4.3)
aMean blood levorphanol level
closely mirrored the ratio of the
actual levels of levorphanol intake
in either treatment group
Only 2 patients with thalamic or
suprathalamic lesions were
responding to morphine
8 patients with CPSP were
sensitive to morphine




aFirst phase: None aSecond
phase: 60% of patients dropped
out because of insufficient pain
relief and/or side effects










Slight side effects (i.e., rise in
pulse rate, sweating, tremor,
salivation, pain, nausea,
faintness) either after naloxone
Slight transitory changes in heart
rate (increase of 10–40 beats/min)
aSevere side effects (constipation,
vomiting, nausea, sedation and
micturition disturbances) occurred
in 58% of patients under morphine
and in 22% of patients under
placebo, independently of dose
aPhysical or psychological
adverse events, treatment failure,
lack of adherence
NS Two patients reported an
increase in pain with transient
abnormal sensations and anxiety
in the ketamine test
NS
CPSP Central Post-Stroke Pain; DS Depression Scale; MPI Multidimensional Pain Inventory; NA  not applicable; NaCl  sodium chloride; NRS Numerical Rating Scale; NS  not specified; OAES Opiate Agonist Effects Scale; OWS 
Opiate Withdrawal Scale; PMS  Profile of Mood States; SC-S  Symptom Complaint Score; SDMT  Symbol Digit Modalities Test; VAS  Visual Analogue Scale; VRS  Visual Rating Scale.

































varied from 4 days to two and a half years. On the other hand,
the placebo-controlled study by Bainton et al. (1992) failed to
demonstrate the efficacy of intravenous administration of
naloxone in alleviating CPSP.
Risk of Bias Assessment
Four of the studies are randomized clinical trials (Bainton
et al., 1992; Attal et al., 2002; Maier et al., 2002; Rowbotham
et al., 2003), one is a single arm trial (Budd, 1985) and three
(Yamamoto et al., 1991; Yamamoto et al., 1997; Saitoh et al.,
2003) are drug challenge tests. Therefore, the included studies
are very heterogeneous in terms of study design. Moreover,
four studies (Budd, 1985; Yamamoto et al., 1991; Yamamoto
et al., 1997; Saitoh et al., 2003) included one single group
without control. In the study by Rowbotham et al. (2003) the
groups compared are high and low strength. The lack of a
control arm can rise some concerns in terms of bias as for
concealment. The population enrolled is heterogeneous across
the eight studies and the number of patients is small for all the
trials except for Maier et al. (2002) and for Rowbotham et al.
(2003); however, the CPSP patients are only two and ten,
respectively. Moreover, in the MONTAS study, with
crossover design, number needed to treat and number
needed to harm are reported to have been calculated only
with reference to first week since the results of the second week
could feel the effect of opioid withdrawal symptoms.
Compliance to treatment has been assessed by pill counts
and repeated urine screening, revealing only minor protocol
violations. Interestingly, double masking was applied to three
trials (Bainton et al., 1992; Attal et al., 2002; Rowbotham et al.,
2003), but for the study by Attal et al. (2002) it was reported
that seven patients and the examiner (in ten cases) had
identified the active treatment, thus impairing blindness. In
the study of Maier et al. (2002), a random generator was used
for patients randomization and the medication package was
blinded. The summary of risk of bias assessment according to
intention-to-treat analysis is reported in Figure 2.
Meta-Analysis and GRADE Evidence Profile
(EP)
The quality of evidence of the two selected outcomes, i.e. analgesic
efficacy of opioids in post-stroke pain and effectiveness on pain-
related domains, was rated through the GRADE system (Guyatt
et al., 2008; Guyatt et al., 2011). The quality assessment was based
on: Limitations; Inconsistency; Indirectness; Imprecision and
Publication bias. For each outcome, the four retrieved
randomized clinical trials (Bainton et al., 1992; Attal et al.,
2002; Maier et al., 2002; Rowbotham et al., 2003) were
subjected to meta-analysis (Figure 3), for the assessment of
absolute and relative risk and width in the CIs to calculate
imprecision, with funnel plot for the evaluation of publication
bias (Figure 4). The GRADE assessment reveals very low quality
of evidence for the outcome of pain reduction and low quality of
evidence for pain-related outcomes. This meta-analysis follows
the Initiative on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) recommendations (Turk et al.,
2003). The core outcome domains for clinical trials of chronic
pain treatment efficacy and effectiveness have been identified as
pain; physical functioning; emotional functioning; participant
ratings of global improvement; symptoms and adverse events;
participant disposition (including adherence to the treatment
regimen and reasons for premature withdrawal from the trial)
(Turk et al., 2003). A meaningful decrease in chronic pain
representing a clinically important difference in pain intensity
is determined as change of approximately 2.0 points of Numerical
Rating Scale (NRS) or 30–36% (Dworkin et al., 2008). Therefore,
administration of opioids (agonists or antagonists) is not
associated to meaningful pain relief (Relative Risk RR 1.05;
95% CI 0.57–1.92; I2  0%; p  0.53; Figure 3) and data are
influenced by the paucity and the design of the studies. Though in
agreement with I2, heterogeneity allows comparison of these
RCTs, RR is not estimable for the study by Rowbotham et al.
(2003), since there is not a real control arm, but a high- and a low-
strength arm. This occurs also for the pain-related outcome, thus
influencing the RR calculation (RR 1.00; 95% CI 0.49–2.05;
FIGURE 2 | Summary of risk of bias assessment for the studies included in qualitative analysis from low to some concerns and high. The mark (+) indicates low risk
of bias and the mark (−) indicates high risk of bias.
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heterogeneity not applicable; Figure 4), since only two RCTs
evaluate this outcome. In this study (Rowbotham et al., 2003) no
significant changes in total mood disturbance and in quality of life
were reported in either treatment group. In the study by Maier
et al. (2002), the improvement of pain-related outcomes exerted
by morphine administration reached statistical significance (p ≤
0.05) only for pain disability and sleep quality. Therefore, RR is
based only on the study by Maier et al. (2002), for pain-related
outcome, thus forest and funnel plots are not reported; evidence
coming from a single trial is uncertain. According to the forest
plot in Figure 3 the results do not favor the experimental
treatment (opioid agonist or antagonist) rather than the
placebo for the outcome of pain reduction.
The GRADE assessment is based on rating of the following
four domains:
(1) Limitations: lack of allocation concealment and/or of
blinding, loss to follow-up, failure to adhere to an
intention to treat analysis and failure to report outcomes.
This key outcome was downgraded for failure of concealment
and blinding (Attal et al., 2002), lack of control arm and large
loss to follow-up (Rowbotham et al., 2003) and minor
protocol violations (Maier et al., 2002) for pain reduction;
for the same reasons, this outcome was downgraded for pain-
related outcomes.
(2) Inconsistency: variability in results across studies can be due
to true differences in treatment effect. The rate of this domain
was downgraded since efficacy is partial across the studies for
pain reduction, and for pain-related outcomes since results
are opposite in the two RCTs.
(3) Indirectness: differences between the population, intervention,
comparator and outcome of interest and those included in the
relevant studies. This key outcome was downgraded both for
pain reduction and for pain-related outcomes since these
studies are conceived for populations including mixed types
of pain and not only post-stroke pain as defined in the PICOS.
FIGURE 3 | Forest plot for efficacy of opioid agonists and antagonists in pain reduction in trials included in the meta-analysis.
FIGURE 4 | Funnel plot for efficacy of opioid agonists and antagonists in pain reduction in trials included in the meta-analysis.
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(4) Imprecision: wide CIs. The retrieved RCTs include relatively
few patients and thus have wide CIs.
(5) Publication bias: studies showing no significant results are
often unpublished. Due to the asymmetry of the funnel plot
and to the paucity of studies, there is strong suspicion of
publication bias. Therefore, the rating of this domain is
defined as “likely”.
The EP with quality assessment and Summary of Findings
(SoF) is reported in Table 3.
DISCUSSION
Post-stroke pain is a complex condition representing both an
underdiagnosed and an undertreated chronic consequence of
cerebrovascular events. Pain after stroke encompasses
neuropathic and nociceptive features and can be either
spontaneous or evoked, constant or intermittent (Klit et al.,
2009). It consists in a variety of pain syndromes going from
CPSP, CRPS, pain secondary to spasticity and musculoskeletal
pain, which may occur with variable prevalence and that can be
present simultaneously being different and difficult to
characterize and adequately treated in each individual patient
(Delpont et al., 2018). Post-stroke pain management is complex,
considering its multifaceted nature and the existence of multiple
pharmacological and non-pharmacological therapeutic
approaches depending on the pain subtype. In fact, according
to the underlying pathophysiology a different management is
needed (Harrison and Field, 2015): local neuromuscular blockade
for pain secondary to spasticity, mechanical stabilization and
rehabilitation with shoulder strapping in musculoskeletal pain,
while first line for neuropathic pain consists in α2δ-1 ligands and
antidepressants and in case of severe resistant pain opioids can
represent an adjuvant treatment. Data and evidence for second
and third-line therapies are even more scant. Also opioid
antagonists could exert some efficacy in pain after stroke since
anomalous perfusion (Strahlendorf et al., 1980) or increased
levels of endogenous opioids (Baskin and Hosobuchi, 1981;
Willoch et al., 2004) can affect the area subjected to stroke.
Indeed, naloxone is studied in acute ischemic stroke. Other
opioids exert peculiar actions like levorphanol that can
interact with both NMDA receptors and serotonin and
norepinephrine uptake (Codd et al., 1995). This systematic
review and meta-analysis evaluated clinical trials investigating
the effect of opioids and opioid antagonists on pain after stroke
and its functional consequences. A small number of studies (i.e., 8
results) met the inclusion criteria and was therefore included in
the qualitative analysis and narrative synthesis (Budd, 1985;
Yamamoto et al., 1991; Bainton et al., 1992; Yamamoto et al.,
1997; Attal et al., 2002; Maier et al., 2002; Rowbotham et al., 2003;
Saitoh et al., 2003). Despite the differences among study design
(i.e., placebo-controlled, single arm, dose-response) and
mechanism of the various opioids investigated (i.e., morphine,
naloxone, levorphanol), nearly all the included studies (except
one) showed an overall only slight analgesic effect of opioid
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NRS, pain relief, pain tolerability) and less consistent effects on
other pain-related symptoms. All the patients included in these
studies suffered from intractable pain resistant to previous
analgesic treatment. Because of the small number of studies
and patients, and the different study design across them, no
robust evidence can be drawn (Sharpe, 1997). Due to their design,
the three drug challenge tests and the study of Budd (1985) are
single group without control and lacking information concerned
with masking of patients, deliverers and assessors, thus rising
some concern in terms of concealment. Double masking was
applied to three trials (Bainton et al., 1992; Attal et al., 2002;
Rowbotham et al., 2003) and, in the MONTAS study, patients
were randomized using a random generator and received the
same blinded medication package. However, in the study by Attal
et al. (2002), blindness was put at risk since seven patients and the
examiner (in ten cases) identified the active treatment. Moreover,
studies differed in terms of pain scales used and they are very
heterogeneous in terms of population enrolled, impairing
directness. Trials are adequately designed but not specifically
for post-stroke pain, e.g. the number of patients is small for all the
trials except for the MONTAS study and the study by
Rowbotham et al. (2003), whereas the CPSP patients are only
two and ten, respectively. Moreover, sample power calculation is
not reported. Overall, in this population, any estimate of effect for
the first PICOS outcome is very uncertain and results are
inconclusive due to the small number of studies and of
patients: in fact, each of the four important GRADE criteria
ranges from moderate/low to very low quality of evidence,
downgrading to very low the overall quality of evidence of
efficacy of opioids (Atkins et al., 2004; Guyatt et al., 2008;
Guyatt et al., 2011). The IMMPACT recommendations
support the importance of physical functioning as core
outcome for pain (Turk et al., 2003), an issue of the utmost
importance in these patients. However, only the study by
Rowbotham et al. (2003) included physical functioning as an
outcome and theMONTAS study highlighted an improvement of
pain-associated sensory and affective variables and disability.
Therefore, there is low quality of evidence for the second
PICOS outcome.
The poor/unclear response of CPSP to opioids is in keeping
with reduced binding to opioids in pain circuitry in CPSP
(Willoch et al., 2004). Indeed, CPSP patients show decreased
brain opioid receptors binding in posterior midbrain, medial
thalamus and the insular, temporal and prefrontal cortices
contralateral to pain, being this pattern different from the
opioid receptors binding occurring in peripheral neuropathic
pain, thus supporting different response of central vs.
peripheral neuropathic pain to opioids (Maarrawi et al., 2007).
Of interest, despite the wide search criteria we used, all the
included studies pertained CPSP, and we found no evidence
on other types of post-stroke pain. Indeed, all the included
studies were quite old and dating prior to the 2009 CPSP
redefinition (Klit et al., 2009), which made the differential
diagnosis between CPSP and other types of post-stroke pain
clearer and more reliable. Pain assessment represents an
important issue in non-communicative patients, who can
have difficulties to describe their pain, contributing to
behavioral disturbances in some neurological conditions
(Scuteri et al., 2017; Scuteri et al., 2018; Scuteri et al.,
2019a; Scuteri et al., 2019b). Indeed, in the real-life clinical
setting, the use of opioids in patients with post-stroke pain,
who are not able to communicate is frequent, but the response
to treatment is unclear (Schuster et al., 2020). Post-stroke
pain can occur also in patients with neurodegenerative
disorders (Scherder and Plooij, 2012) and clinical trials to
assess the efficacy and safety of opioids are needed, being the
treatment of pain often inappropriate in this population
(Scuteri et al., 2017; Scuteri et al., 2018; Scuteri et al.,
2020a; Scuteri et al., 2020b). Future double-blind
randomized clinical trials designed specifically for post-
stroke pain, methodology and statistical power are needed
to assess the efficacy and safety of opioids in post-stroke pain
and to understand the impact of pain treatment on physical
function. In fact, being post-stroke pain often severe, it may
be resistant to first line treatments, as it occurs in all of the
studies included in the analysis; the latter condition makes
treatment with opioids sometimes necessary. In these eight
studies morphine induced nausea, somnolence, headache and
severe side effects (in 58% of patients of the study by Maier
et al. (2002), consisting in constipation, vomiting, nausea,
sedation and micturition disturbances), also psychological
effects were reported with levorphanol and naloxone caused
slight increase in pulse rate, sweating, tremor, salivation, pain,
nausea and faintness. In the light of the most rigorous analysis
of the literature, it is conceivable that opioid use within a time
frame of no longer than 12 weeks is not linked to respiratory
depression and to the potential for abuse with overdose death
(Dowell et al., 2016). However, further evidence is necessary
for the best clinical use of these effective analgesics, also
limiting the most serious consequences of inappropriate
opioids prescription.
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